China's drug regulator granted Zhejiang Hisun Pharmaceutical (SHA:600267) subsidiary Hanhui Pharmaceutical a supplementary drug approval for its Idarubicin Hydrochloride Injection, according to a Friday filing with the Shanghai bourse.
The injection will help induce remission of treatment-naïve, as well as relapsed and refractory acute non-lymphocytic leukemia in adults.
As stated in the filing, it also serves as a treatment for acute lymphoblastic leukemia.
Shares rose 4% during afternoon trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments